Cara Therapeutics cares about pain therapy. The clinical-stage biopharmaceutical company focuses on developing and commercializing new chemical products designed to alleviate pain by selectively targeting kappa opioid receptors. Its proprietary class of product candidates target the body's peripheral nervous system. In test with patients with moderate-to-severe pain they have have demonstrated efficacy without inducing many of the undesirable side effects often associated with pain therapeutics. Cara's most advanced product candidate, is intravenous CR845. The company filed to go public in 2014.
See detailed business credit reports on other businesses or your own.
See detailed profiles for insights and prospects on this company's top competitors.
Essential information for a successful call
EMPLOYEES (All Sites)
- ASSETS (MIL USD) 233
REVENUE (MIL USD)
- TICKER SYMBOL CARA
- Incorporated 2004
- FISCAL YEAR END DEC
- SALES GROWTH % 47.64%
Get in Touch with 4 Contacts and 5 Principals*
Derek ChalmersPresident and Chief Executive Officer
MANI MOHINDRUChief Financial Officer and Officer
FREDERIQUE MENZAGHISenior Vice President
SCOTT M TERRILLIONGeneral Counsel and Secretary and Officer